MyMD Pharmaceuticals Enrolls First Individual in Phase 2 Scientific Test of MYMD-1 as a Treatment for Delaying Aging and Expanding Healthy And Balanced Life-span

MyMD Pharmaceuticals, Inc. MYMD Stock News (” MyMD” or “the Company”), a scientific phase pharmaceutical firm devoted to extending healthy life-span, today introduced that the very first patient has actually been enrolled in the Firm’s Stage 2 scientific test of lead prospect MYMD-1, an oral immune regulatory authority medicine, as a therapy for delaying aging as well as broadening healthy and balanced lifespan.

The primary endpoint for the Stage 2 double-blind, placebo-controlled clinical test is to achieve a reduction in the distributing levels of (TNF-α), growth necrosis factor receptor I (TNFRI) as well as IL-6. TNF-α and also IL-6 are the healthy proteins in the body that trigger swelling as well as aid activate the process of aging. The secondary procedures of the trial will certainly be the safety and security, tolerability, as well as pharmacokinetics in this population of patients.

” In a Stage 1 medical trial of MYMD-1, we demonstrated the medicine’s statistically substantial efficiency in decreasing degrees of TNF-α, a principal in creating pathological aging, in the blood. The FDA has accepted TNF-α reduction as the primary endpoint for our Phase 2 research study, which our company believe settings us well for a successful Stage 2 result,” said Chris Chapman, M.D., Head Of State, Supervisor as well as Chief Medical Policeman of MyMD. “The initiation of patient enrollment in this research developments our goal to slow down the aging process, prevent loss of muscle tissue in aging, limit frailty, and expand healthy life expectancy.”

MyMD has actually stated that there are no FDA-approved medicines for dealing with aging conditions and extending healthy and balanced life-span human beings, a market expected to be at least $600 billion by 20251 according to a major financial investment financial institution. TNF-α blockers are the most prescribed medications by profits, a global market of approximately $40 billion each year,2 as well as, according to Nature Aging journal,3 a slowdown in aging that would certainly raise life span by one year deserves $38 trillion and by ten years deserves $367 trillion.

In addition to aging, MYMD-1’s unique action in controling the body immune system and also treating persistent inflammation is being established for the treatment of autoimmune condition, consisting of rheumatoid joint inflammation (RA), multiple sclerosis (MS), diabetes, as well as inflammatory bowel disease.

” We plan to start writing methods for a Stage 2 pilot research of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman kept in mind. “The rising prevalence of rheumatoid arthritis and other autoimmune and inflammatory diseases are driving need for TNF inhibitors like MYMD-1, and also we believe our by mouth administered medication with extremely reduced toxicity would certainly be turbulent to the $60 billion market for RA if approved by the FDA for this sign.”

Rheumatoid arthritis impacts around 40 million individuals worldwide.4.

Regarding MYMD-1.

Initially developed for autoimmune illness, MYMD-1’s primary objective is to reduce the aging process, protect against sarcopenia as well as frailty, and also extend healthy life expectancy. Because it can go across the blood-brain obstacle and also access to the central nerves (CNS), MYMD-1 is likewise placed to be a possible treatment for brain-related conditions. Its device of action as well as efficiency in diseases including numerous sclerosis (MS) and thyroiditis have actually been examined via cooperations with several scholastic institutions. MYMD-1 is also revealing guarantee in pre-clinical researches as a possible treatment for message- COVID-19 complications and as an anti-fibrotic as well as anti-proliferation restorative.

MYMD-1 has actually shown performance in pre-clinical research studies in regulating the body immune system by executing as a selective inhibitor of lump necrosis factor-alpha (TNF-α), a motorist of persistent swelling. Unlike other therapies, MYMD-1 has been displayed in these pre-clinical studies to precisely block TNF-α when it comes to be overactivated in autoimmune diseases and cytokine tornados, however not block it from doing its regular task of being an initial responder to any kind of routine sort of moderate infection. MYMD-1’s convenience of dental dosing is an additional differentiator contrasted to currently offered TNF-α blockers, all of which require delivery by shot or infusion. No accepted TNF inhibitor has actually ever before been dosed by mouth. Additionally, the drug is not immunosuppressive and also has actually not been revealed to cause the major adverse effects typical with conventional therapies that deal with swelling.

Regarding MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical stage pharmaceutical company dedicated to expanding healthy lifespan, is focused on creating two novel therapeutic platforms that treat the reasons for illness instead of just addressing the symptoms. MYMD-1 is a medicine platform based on a professional stage small particle that regulates the immune system to control TNF-α, which drives chronic inflammation, as well as various other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to postpone aging, boost longevity, as well as deal with autoimmune illness as well as COVID-19- linked clinical depression. The Company’s second medicine system, Supera-CBD, is being established to deal with chronic pain, dependency and epilepsy. Supera-CBD is an unique artificial by-product of cannabidiol (CBD) and is being developed to attend to and also improve upon the swiftly growing CBD market, which includes both FDA authorized medicines and CBD items not currently controlled as medicines. For additional information, see www.mymd.com.